Testing for all metastatic breast cancer patients may be an optimal strategy for identifying additional patients with increased risk as well as response to targeted therapies.

A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients.

Investigators are exploring the molecular mechanisms behind the association of chronic inflammation and colon cancer.

Inflammation synergizes with a cell’s intrinsic genetic program to promote the development of pancreatic cancer.

Jason MacGurn and colleagues have characterized a “rheostat” that sets WNT pathway signaling in breast cancer cells.

Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.

Breast cancer researchers at Vanderbilt-Ingram Cancer Center have secured a fourth round of continuous Specialized Program of Research Excellence funding.

Colorectal cancer researchers from Vanderbilt-Ingram Cancer Center (VICC) have been awarded a Specialized Program of Research Excellence grant from the National Cancer Institute (NCI).

A previously unrecognized role for a cell surface receptor may open new therapeutic options for the treatment of fibrotic diseases.

Michael Savona, MD, professor of Medicine and Cancer Biology, and director of Hematology Research at Vanderbilt-Ingram Cancer Center, has received a competitive grant award from the Edward P. Evans Foundation.